Pitcairn Co. Sells 13,769 Shares of DexCom, Inc. (NASDAQ:DXCM)

Pitcairn Co. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 38.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,613 shares of the medical device company’s stock after selling 13,769 shares during the period. Pitcairn Co.’s holdings in DexCom were worth $1,449,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Insight Partners LLC raised its position in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after buying an additional 90 shares in the last quarter. HM Payson & Co. boosted its position in shares of DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares during the last quarter. Clear Creek Financial Management LLC grew its holdings in shares of DexCom by 4.2% during the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after purchasing an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC increased its position in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after purchasing an additional 152 shares during the last quarter. Finally, Securian Asset Management Inc. raised its stake in DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after purchasing an additional 161 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research reports. Wells Fargo & Company upped their price objective on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Raymond James reduced their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Robert W. Baird lifted their price target on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 2.2 %

DXCM opened at $72.83 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a 50 day moving average price of $70.61 and a 200-day moving average price of $89.83. The stock has a market capitalization of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.